

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC.,  
Petitioner

v.

REGENERON PHARMACEUTICALS, INC.,  
Patent Owner

---

Case IPR2021-00880  
Patent No. 9,669,069 B2

---

**PRELIMINARY RESPONSE OF PATENT OWNER  
REGENERON PHARMACEUTICALS, INC.**

## TABLE OF CONTENTS

	Page No.
I. INTRODUCTION .....	1
II. THE PETITION SHOULD BE REJECTED FOR CIRCUMVENTING THE WORD LIMIT AND OBFUSCATING ITS GROUNDS.....	4
A. The Petition Violates the Word Limit.....	4
B. The Petition Fails the Particularity Requirement.....	5
C. Janssen Pharmaceuticals, Inc. Is a Real Party-in-Interest.....	9
III. THE BOARD SHOULD DENY INSTITUTION UNDER 35 U.S.C. § 325(D).....	10
A. The Examiner Considered the Same or Substantially the Same Art ( <i>Becton, Dickinson</i> Factors (a), (b), and (d)) .....	10
1. Dixon.....	10
2. Heier-2009 .....	11
3. Regeneron (30-April-2009) .....	13
4. Mitchell .....	14
5. '758 Patent and Dix.....	14
B. Petitioner Fails to Argue that the Examiner Erred in a Manner Material to Patentability ( <i>Becton, Dickinson</i> Factors (c), (e), and (f)).....	16
IV. THE BOARD SHOULD DENY INSTITUTION BECAUSE PETITIONER FAILS TO MAKE ITS THRESHOLD SHOWING THAT AT LEAST ONE CHALLENGED CLAIM IS UNPATENTABLE.....	17
A. Grounds 1-5: Petitioner Fails to Establish the “Assessed by a Physician” Limitation Is Anticipated or Obvious .....	18

1.	Claim Construction .....	18
a.	“Based On Visual and/or Anatomical Outcomes as Assessed by a Physician or Other Qualified Medical Professional” .....	20
2.	Grounds 1-4: Petitioner Fails to Establish that Heier-2009, Dixon or Regeneron (30-April-2009) Inherently or Expressly Discloses the “Assessed by a Physician or Other Qualified Medical Professional” Limitation (All Challenged Claims) .....	24
a.	Heier-2009 (Ground 1) .....	24
b.	Dixon (Ground 2 and 4).....	27
c.	Regeneron (30-April-2009) (Ground 3) .....	29
3.	Under Petitioner’s Definition of the POSA, Petitioner Fails to Show that Heier-2009, Dixon, or Regeneron (30-April-2009) Is Enabled .....	29
4.	Ground 5: Petitioner Fails to Satisfy Its Burden that the “Assessed by a Physician or Other Qualified Medical Professional” Is Obvious (All Challenged Claims) .....	31
<b>B.</b>	Grounds 1-4 (§ 102 Anticipation): Petitioner Fails to Establish that the Disclosure of “VEGF Trap-Eye” in Heier-2009, Dixon, or Regeneron (30-April-2009) Anticipates the Recited Amino Acid or Nucleic Acid Sequences.....	31
1.	Petitioner Fails to Establish that “VEGF Trap-Eye” Was Known in the Art to Correspond to SEQ ID NO: 2 (Claims 1 and 8-11) .....	32
a.	Petitioner and Its Expert Repeatedly Equate “Aflibercept” with All Variations of “VEGF Trap” .....	34
b.	Petitioner Fails to Address Uncertainty in the Art as to the Amino Acid Sequence of “VEGF Trap-Eye” .....	38

2.	Petitioner Fails to Establish that “VEGF Trap-Eye” Was Known in the Art to Be Encoded by SEQ ID NO: 1 (Claim 12) .....	40
<b>C.</b>	<b>Ground 4: Petitioner Fails to Demonstrate that There Is a Reasonable Likelihood that at Least One of the Challenged Clams Is Anticipated or Rendered Obvious by VIEW1/2 as Disclosed in Dixon .....</b>	<b>41</b>
1.	Petitioner Fails to Establish that the 8-Week Dosing Arm of the VIEW Clinical Trial Anticipates the Claimed PRN Dosing Regimen (All Challenged Claims) .....	42
2.	Petitioner Fails to Establish that the 8-Week Dosing Arm of the VIEW Clinical Trial Renders Obvious the Claimed PRN Dosing Regimen (All Challenged Claims) .....	45
<b>D.</b>	<b>Ground 5: Petitioner Fails to Demonstrate that There Is a Reasonable Likelihood that at Least One of the Challenged Clams Is Rendered Obvious .....</b>	<b>47</b>
<b>E.</b>	<b>Petitioner’s Argument Against Objective Evidence Should Be Rejected .....</b>	<b>52</b>
<b>V.</b>	<b>CONCLUSION.....</b>	<b>57</b>

## TABLE OF AUTHORITIES

	<b>Page(s)</b>
<b>Cases</b>	
<i>ABS Global, Inc. v. Cytonome/ST, LLC</i> , IPR2021-00306, Paper 13 (Jun. 7, 2021) .....	11, 16
<i>Adaptics Ltd. v. Perfect Co.</i> , IPR2018-01596, Paper 20 (Mar. 6, 2019) .....	5
<i>Advanced Bionics, LLC v. MED-EL Elektromedizinische Gerate GmbH</i> , IPR2019-01469, 2020 WL 740292 (Feb. 13, 2020) .....	16
<i>Advanced Display Sys., Inc. v. Kent State Univ.</i> , 212 F.3d 1272 (Fed. Cir. 2000) .....	42
<i>Amgen, Inc. v. Alexion Pharms., Inc.</i> , IPR2019-00739, Paper 15 (Aug. 30, 2019) .....	41
<i>Apple, Inc. v. ITC</i> , 725 F.3d 1356 (Fed. Cir. 2013) .....	52
<i>AstraZeneca AB v. Aurobindo Pharma Ltd.</i> , 232 F. Supp. 3d 636 (D. Del. 2017) .....	46
<i>Belden Inc. v. Berk-Tek LLC</i> , 805 F.3d 1064 (Fed. Cir. 2015) .....	51
<i>Boragen, Inc. v. Syngenta Participations AG</i> , IPR2020-00124, 2020 WL 2206972 (May 5, 2020) .....	14
<i>C R Bard Inc. v. AngioDynamics, Inc.</i> , 979 F.3d 1372 (Fed. Cir. 2020) .....	23
<i>Cisco Sys., Inc. v. C-Cation Techs., LLC</i> , IPR2014-00454, Paper 12 (Aug. 29, 2014) .....	26
<i>Continental Can Co. USA v. Monsanto Co.</i> , 948 F.2d 1264 (Fed. Cir. 1991) .....	33
<i>Dropworks, Inc. v. Univ. of Chi.</i> , IPR2021-00100, Paper 9 (May 14, 2021) .....	15
<i>EIK Eng’g Sdn. Bhd. v. Wilco Marsh Buggies &amp; Draglines, Inc.</i> , IPR2020-00344, Paper 7 (June 23, 2020), <i>reh’g denied</i> , IPR2020-00344, Paper 12 (Mar. 4, 2021) .....	9

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.